Innovating pharmaceuticals for life

October 6, 2016

Marathon Pharmaceuticals Names Rick Munschauer, MD, FAAN as Chief Medical Officer

NORTHBROOK, Ill. – Oct. 6 2016 – Marathon Pharmaceuticals LLC, a biopharmaceutical company developing treatments for rare diseases, today announced that Rick Munschauer, MD, FAAN, has joined the company as Vice President and Chief Medical Officer, effective immediately.

In his new role Dr. Munschauer will oversee clinical development, medical and scientific affairs activities for Marathon. He is a member of the Marathon executive team and will be based at the company’s headquarters in Northbrook, Illinois.

Dr. Munschauer previously served as Vice President of Medical Affairs, Neurology and Immunology at EMD Serono. Prior to that, he held successive roles of Chief Medical Advisor, Global Head of Medical Affairs, and Vice President of US Medical Affairs at Biogen.

Before entering the pharmaceutical industry, Dr. Munschauer had a 25-year career in academic medicine and was Smith Professor and Chair of the Department of Neurology at the State University of New York at Buffalo. He holds board certifications in neurology, internal medicine and critical care.

“Dr. Munschauer’s extensive experience in clinical trial design and execution from both academic and industry perspectives makes him the ideal candidate for serving as Marathon’s Chief Medical Officer,” said Jeff Aronin, Chief Executive Officer, Marathon Pharmaceuticals. “His leadership and expertise come at a vital time for our company as we continue developing a more robust pipeline.”

Dr. Munschauer completed his internal medicine and neurology training at Johns Hopkins University and earned his MD degree at McGill University. He also holds an MSc in Mechanical Engineering from the Massachusetts Institute of Technology and a BSE in Electrical Engineering from Duke University.

About Marathon Pharmaceuticals

Marathon Pharmaceuticals, LLC, is a biopharmaceutical company that develops treatments for rare diseases, with a focus on patients who currently have no treatment options. The company’s pipeline of new medicines includes treatments for rare neurological and movement disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago, Cambridge, MA, New Jersey and Washington D.C.

Media Contact

Dan Boyle
(818) 209-1692


Next Article - Oct 31, 2016

Marathon Pharmaceuticals Names Wanda Moebius Vice President of Communications


Previous Article - Aug 30, 2016

Marathon Pharmaceuticals Announces Neurology Publication of Pivotal Phase 3 Data for Deflazacort for Duchenne Muscular Dystrophy